report thumbnailCOVID-19 Vaccine Addressable Market

COVID-19 Vaccine Addressable Market Is Set To Reach 41.6 USD billion By 2033, Growing At A CAGR Of 21.2

COVID-19 Vaccine Addressable Market by By Vaccine Type: (mRNA vaccines, DNA vaccines, Vector vaccines, Protein subunit vaccines, Inactivated vaccines, Whole virion vaccines ), by By Application: (Prophylaxis, Treatment ), by By End User: (Healthcare professionals, General public), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2025-2033


Base Year: 2024

135 Pages
Market Research Future Logo

COVID-19 Vaccine Addressable Market Is Set To Reach 41.6 USD billion By 2033, Growing At A CAGR Of 21.2


Key Insights

The COVID-19 Vaccine Addressable Market size was valued at USD 41.6 USD billion in 2023 and is projected to reach USD 159.81 USD billion by 2032, exhibiting a CAGR of 21.2 % during the forecast period. COVID-19 vaccine addressable refers to the ability to identify, reach, and target specific populations or groups that are eligible or in need of COVID-19 vaccination. This term is often used in discussions related to the distribution and administration of vaccines, especially as it pertains to ensuring equitable access across different regions, age groups, and demographics. The concept of "addressable" typically includes the identification of individuals or populations who may benefit from vaccination

COVID-19 Vaccine Addressable Market Research Report - Market Size, Growth & Forecast

COVID-19 Vaccine Addressable Trends

  • Growing demand for vaccines due to the increase in COVID-19 cases
  • Increase in government funding for vaccine research and development
  • Development of new and improved vaccines
  • Collaborations between pharmaceutical companies and research institutions
  • Expansion of vaccine manufacturing capacity

Driving Forces: What's Propelling the COVID-19 Vaccine Addressable Market

  • Increasing prevalence of COVID-19 cases: The COVID-19 pandemic has resulted in a significant increase in the number of cases worldwide. This has led to a growing demand for vaccines to prevent the spread of the virus.
  • Government initiatives to procure and distribute vaccines: Governments around the world have launched initiatives to procure and distribute vaccines to their populations. This has provided a major boost to the market for COVID-19 vaccines.
  • Development of new and improved vaccines: Pharmaceutical companies are continuously developing new and improved vaccines to combat COVID-19. These vaccines are more effective and have fewer side effects, which is driving demand for them.
  • Collaborations between pharmaceutical companies and research institutions: Pharmaceutical companies are collaborating with research institutions to develop and test new vaccines. This collaboration is helping to accelerate the development of vaccines.
  • Expansion of vaccine manufacturing capacity: Vaccine manufacturers are expanding their production capacity to meet the growing demand for vaccines. This is ensuring that there is enough supply of vaccines to meet the needs of the population.

COVID-19 Vaccine Addressable Market Growth

Challenges and Restraints in COVID-19 Vaccine Addressable Market

  • Vaccine hesitancy: Some people are hesitant to get vaccinated against COVID-19 due to concerns about safety and efficacy. This hesitancy is a major challenge to the market for COVID-19 vaccines.
  • Supply chain disruptions: The COVID-19 pandemic has disrupted global supply chains, which has made it difficult to procure raw materials and components for vaccine manufacturing. This has led to delays in vaccine production and delivery.
  • Cost of vaccines: The cost of COVID-19 vaccines is a major concern for many people. This is especially true in developing countries, where people have limited access to healthcare.
  • Long-term efficacy of vaccines: The long-term efficacy of COVID-19 vaccines is still unknown. This is a concern for some people, who may be hesitant to get vaccinated until more data is available.
  • Emergence of new variants: The emergence of new variants of COVID-19 is a concern for vaccine manufacturers. These variants may be more resistant to vaccines, which could reduce their efficacy.

Emerging Trends in COVID-19 Vaccine Addressable

  • Development of mRNA vaccines: mRNA vaccines are a new type of vaccine that has been shown to be highly effective against COVID-19. These vaccines are easy to manufacture and can be quickly adapted to new variants of the virus.
  • Use of artificial intelligence (AI): AI is being used to develop and test new vaccines. This is helping to accelerate the development process and identify potential candidates.
  • Personalized vaccines: Personalized vaccines are being developed to target specific individuals. These vaccines are more effective and have fewer side effects.
  • Combination vaccines: Combination vaccines are being developed to protect against multiple strains of COVID-19. This is helping to reduce the need for multiple vaccinations.
  • Global vaccine distribution: Global vaccine distribution is a major challenge. Pharmaceutical companies and governments are working together to ensure that vaccines are distributed equitably around the world.

Growth Catalysts in COVID-19 Vaccine Addressable Industry

  • Government support: Governments around the world are providing financial support to vaccine manufacturers. This is helping to accelerate the development and production of vaccines.
  • Public-private partnerships: Public-private partnerships are being formed to develop and distribute vaccines. These partnerships are bringing together the resources of government agencies, pharmaceutical companies, and non-profit organizations.
  • Technological advancements: Technological advancements are helping to accelerate the development and production of vaccines. These advancements include the use of mRNA vaccines and AI.
  • Increasing demand for vaccines: The growing demand for vaccines is a major growth catalyst for the market. This demand is being driven by the increasing prevalence of COVID-19 cases and the desire to protect people from the virus.

Market Segmentation: COVID-19 Vaccine Addressable Analysis

By Vaccine Type:

  • mRNA vaccines
  • DNA vaccines
  • Vector vaccines
  • Protein subunit vaccines
  • Inactivated vaccines
  • Whole virion vaccines

By Application:

  • Prophylaxis
  • Treatment

By End User:

  • Healthcare professionals
  • General public

Leading Players in the COVID-19 Vaccine Addressable Market

Significant developments in COVID-19 Vaccine Addressable Sector

  • In December 2020, Pfizer and BioNTech announced that their COVID-19 vaccine was 95% effective in preventing symptomatic COVID-19.
  • In January 2021, Moderna announced that its COVID-19 vaccine was 94% effective in preventing symptomatic COVID-19.
  • In February 2021, Johnson & Johnson announced that its COVID-19 vaccine was 66% effective in preventing symptomatic COVID-19.
  • In March 2021, AstraZeneca and Oxford University announced that their COVID-19 vaccine was 70% effective in preventing symptomatic COVID-19.
  • In April 2021, Novavax announced that its COVID-19 vaccine was 90% effective in preventing symptomatic COVID-19.

Comprehensive Coverage COVID-19 Vaccine Addressable Market Report

The report provides comprehensive coverage of the following:

  • Market size and growth forecasts
  • Key market trends and drivers
  • Challenges and restraints
  • Market segmentation
  • Competitive landscape
  • Company profiles
  • Recent developments
  • Future outlook

Regional Insight

The COVID-19 vaccine addressable market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is the largest market for COVID-19 vaccines, followed by Europe. Asia-Pacific is expected to be the fastest-growing market for COVID-19 vaccines during the forecast period.

Pricing Analysis

The price of COVID-19 vaccines varies depending on the type of vaccine, the manufacturer, and the country where it is purchased. In the United States, the Pfizer-BioNTech vaccine costs $19.50 per dose, the Moderna vaccine costs $15.25 per dose, and the Johnson & Johnson vaccine costs $10 per dose.

Import And Export Analysis

The import and export of COVID-19 vaccines is a major concern for governments around the world. Some countries have banned the export of vaccines, while others have imposed tariffs on imported vaccines. This is making it difficult for countries to access the vaccines they need to protect their populations.

Segmentation

The COVID-19 vaccine addressable market is segmented into the following categories:

  • By Vaccine Type: mRNA vaccines, DNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, whole virion vaccines
  • By Application: Prophylaxis, treatment
  • By End User: Healthcare professionals, general public

Patent/Trademark Analysis

There are a number of patents and trademarks associated with COVID-19 vaccines. These patents and trademarks protect the intellectual property of the companies that developed the vaccines.

COVID-19 Vaccine Addressable Market REPORT HIGHLIGHTS

AspectsDetails
Study Period 2019-2033
Base Year 2024
Estimated Year 2025
Forecast Period2025-2033
Historical Period2019-2024
Growth RateCAGR of 21.2% from 2019-2033
Segmentation
    • By By Vaccine Type:
      • mRNA vaccines
      • DNA vaccines
      • Vector vaccines
      • Protein subunit vaccines
      • Inactivated vaccines
      • Whole virion vaccines
    • By By Application:
      • Prophylaxis
      • Treatment
    • By By End User:
      • Healthcare professionals
      • General public
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Russia
      • Benelux
      • Nordics
      • Rest of Europe
    • Middle East & Africa
      • Turkey
      • Israel
      • GCC
      • North Africa
      • South Africa
      • Rest of Middle East & Africa
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • ASEAN
      • Oceania
      • Rest of Asia Pacific

Frequently Asked Questions

Related Reports


About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

We use cookies to enhance your experience.

By clicking "Accept All", you consent to the use of all cookies.

Customize your preferences or read our Cookie Policy.